通过初级RNA包装抑制剂抑制HIV-1复制的抑制
Marc Mirande1, Frédéric Subra1, Clémence Richetta1
1Laboratoire de Biologie et Pharmacologie Appliquée (LBPA), UMR 8113 CNRS, ENS Paris-Saclay, Université Paris-Saclay, Gif-sur-Yvette, France.
mBio
|October 23, 2025
概括
针对人体免疫缺陷病毒1型 (HIV-1) 包装tRNA3Lys的新药抑制病毒复制. 这些化合物破坏了必要的相互作用,导致非传染性病毒颗粒和减少tRNA3Lys合并.
科学领域:
- 病毒学 病毒学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 人类免疫缺陷病毒1型 (HIV-1) 复制依赖于病毒组装期间的包装转移RNA (tRNA).
- 这种包装过程涉及GagPol,线粒体lysyl-tRNA合成酶和tRNA3Lys的复合体,这对于启动逆转录至关重要.
- 目前的HIV疗法针对病毒生命周期的不同阶段,但需要新的策略来克服抗性.
研究的目的:
- 为了确定抑制GagPol和线粒体 lysyl-tRNA合成酶之间的相互作用的分子.
- 评估这些分子在阻止HIV-1复制的有效性.
- 探索针对tRNA包装步骤的潜力,以开发新的抗病毒药物.
主要方法:
- 采用了体外测试来选一种化学库,以检测GagPol-lysyl-tRNA合成酶相互作用的抑制剂.
- 选择的抑制分子被测试了它们在活体试验中抑制HIV-1复制的能力.
- 病毒颗粒的产生,感染性和tRNA3Lys含量在已识别的抑制剂的存在下进行了分析.
主要成果:
- 他们分离了三种分子,这些分子有效地破坏了目标相互作用.
- 这些分子显著降低了HIV-1颗粒的产生 (IC50在5μM) 和感染力.
- 抑制剂治疗导致tRNA3Lys包装到病毒的减少,导致复制缺陷粒子.
结论:
- 艾滋病毒-1tRNA包装步骤是抗病毒药物开发的可行目标.
- 已识别的分子代表了一种具有新作用机制的新型HIV-1抑制剂.
- 这些抑制剂为开发具有独特抗HIV-1抗药特征的药物提供了潜力.
相关概念视频
Retrovirus Life Cycles
49.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.3K
RNA Interference
27.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.8K
Experimental RNAi
7.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K
Viruses with RNA Genomes
808
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
808
siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K


